ORYZF (Oryzon Genomics) Forward PE Ratio: 522.15 (As of Jul. 06, 2026)


ORYZF Oryzon Genomics SA ORYZF
31 GF Score
Price $3.66
View Full Analysis

What is Oryzon Genomics Forward PE Ratio?

Oryzon Genomics ORYZF 31 Forward PE Ratio is 522.15 as of Jul. 06, 2026. GuruFocus rates ORYZF with a GF Score™ of 31/100. Among 354 Biotechnology companies, Oryzon Genomics ranks worse than 97.18% on this metric.

Oryzon Genomics's Forward PE Ratio for today is 522.15.

Oryzon Genomics's PE Ratio without NRI for today is 0.00.

Oryzon Genomics's PE Ratio (TTM) for today is 0.00.


Oryzon Genomics  (OTCPK:ORYZF) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Oryzon Genomics Forward PE Ratio Related Terms


Oryzon Genomics Forward PE Ratio Historical Data

* Premium members only.

The historical data trend for Oryzon Genomics's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oryzon Genomics Forward PE Ratio Chart

Oryzon Genomics Annual Data
Trend 2024-12 2025-12
Forward PE Ratio
30.57 108.39

Oryzon Genomics Quarterly Data
2024-09 2024-12 2025-03 2025-06 2025-09 2025-12
Forward PE Ratio 18.25 30.57 310.00 115.12 96.57 108.39

ORYZF vs VRTX, REGN, ALNY: Forward PE Ratio Comparison

For the Biotechnology subindustry, Oryzon Genomics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oryzon Genomics Forward PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oryzon Genomics's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Oryzon Genomics's Forward PE Ratio falls into.


ORYZF
31GF Score
Oryzon Genomics SA ORYZF
Forward PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oryzon Genomics Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Frequently Asked Questions Learn more about Forward PE Ratio →
What does a Forward PE Ratio of 522.15 mean?
Oryzon Genomics (ORYZF) has a Forward PE Ratio of 522.15 as of Jul. 06, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Oryzon Genomics and its competitors. According to the industry distribution chart, Oryzon Genomics ranks #344 out of 354 companies in the Biotechnology industry, placing it in the top 97.2%.
Is Oryzon Genomics' Forward PE Ratio too high?
Oryzon Genomics' current Forward PE Ratio is 522.15. The Biotechnology industry median Forward PE Ratio is 22.33. Oryzon Genomics' value of 522.15 is 2238.9% above this industry median. Based on the distribution chart, Oryzon Genomics ranks #344 out of 354 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oryzon Genomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Oryzon Genomics' Forward PE Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oryzon Genomics ranks #344 out of 354 companies for Forward PE Ratio. This places Oryzon Genomics in the lower half of its industry. The industry median Forward PE Ratio is 22.33. Oryzon Genomics' value of 522.15 is 2238.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 22.33, based on 354 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oryzon Genomics's current Forward PE Ratio of 522.15 is 2238.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Oryzon Genomics and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 22.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oryzon Genomics's current Forward PE Ratio is 522.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oryzon Genomics stock overvalued right now?
Oryzon Genomics (ORYZF) has a current Forward PE Ratio of 522.15. The current Forward PE Ratio is 522.15 and 2238.9% above the Biotechnology industry median of 22.33. Oryzon Genomics' overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Oryzon Genomics (ORYZF), the current Forward PE Ratio is 522.15 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oryzon Genomics Business Description

Other Exchanges 0RDB:UKORY:SpainORN:Germany
Address Sant Ferran 74, Cornellà de Llobregat, Barcelona, ESP, 08940
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.
31GF Score

Get the complete analysis for ORYZF

Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.66
Price